Renal Function Outcomes with Long-Term Esaxerenone Treatment

Abstract

Esaxerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), has emerged as a novel therapeutic agent for the management of hypertension and chronic kidney disease (CKD). This review synthesizes current evidence regarding its long-term impact on renal function, emphasizing clinical outcomes, mechanistic underpinnings, and guideline-based recommendations. By collating data from recent randomized controlled trials and real-world studies, we explore esaxerenone’s role in preserving renal function, its safety profile, and its place in contemporary nephrology practice.

Introduction

The management of chronic kidney disease and hypertension has evolved with the advent of selective mineralocorticoid receptor antagonists. Esaxerenone, with its high selectivity and favorable pharmacokinetic profile, offers potential advantages over traditional MRAs. Understanding its long-term effects on renal function is critical for optimizing care in patients at risk of progressive nephropathy, particularly those with comorbid hypertension and proteinuria.

Epidemiology / Disease Burden

Chronic kidney disease affects over 10% of the global population, with hypertension as both a cause and consequence of renal dysfunction. The increasing prevalence of diabetic nephropathy and the aging population further underscore the need for therapies that not only control blood pressure but also confer renal protection. Despite advances in renin-angiotensin-aldosterone system (RAAS) blockade, substantial residual risk for CKD progression remains.

Pathophysiology

Mineralocorticoid receptor overactivation in the kidney leads to sodium retention, potassium excretion, inflammation, and fibrosis—pathways central to the progression of hypertensive nephropathy and CKD. Traditional steroidal MRAs, such as spironolactone and eplerenone, have shown efficacy in attenuating these mechanisms, but their use is often limited by adverse effects such as hyperkalemia and hormonal side effects. Esaxerenone’s non-steroidal structure confers greater selectivity, potentially reducing off-target actions and enabling more effective long-term blockade of mineralocorticoid-induced renal injury.

Risk Factors

Patients with diabetes mellitus, longstanding hypertension, obesity, and established cardiovascular disease are at heightened risk for CKD progression. Additional risk factors include genetic predisposition, smoking, dyslipidemia, and poor glycemic control. The presence of albuminuria and reduced estimated glomerular filtration rate (eGFR) are key markers for adverse renal outcomes, guiding the selection of targeted therapies such as MRAs.

Clinical Features

CKD presents insidiously, often recognized only after significant nephron loss. Clinical features may include hypertension, peripheral edema, proteinuria, and, in advanced stages, uremic symptoms such as fatigue, anorexia, and cognitive impairment. Early intervention is crucial to mitigate irreversible renal damage, necessitating therapies that provide both hemodynamic and anti-fibrotic benefits.

Diagnosis

Diagnosis of CKD is based on persistent reduction in eGFR (<60 mL/min/1.73 m²) and/or albuminuria (>30 mg/g) over at least three months. Laboratory evaluation includes serum creatinine, eGFR calculation, urine albumin-to-creatinine ratio (UACR), and assessment of electrolytes. Imaging and histopathology are reserved for atypical presentations or suspicion of secondary causes. Monitoring is essential during MRA therapy to detect hyperkalemia and changes in renal parameters.

Treatment & Management

Standard management of CKD and hypertensive nephropathy focuses on RAAS inhibition, glycemic and lipid control, and blood pressure reduction. Esaxerenone, typically initiated at low doses and titrated based on renal function and potassium levels, demonstrates robust antihypertensive efficacy. Clinical trials, such as ESAX-HTN and ESAX-DN, have shown significant reductions in albuminuria and preservation of eGFR over periods extending to one year or more. Dose adjustments and careful monitoring are imperative in patients with advanced CKD.

Recent Advances / Emerging Therapies

The development of esaxerenone represents a significant advance in the selective targeting of mineralocorticoid receptors. In contrast to steroidal MRAs, esaxerenone’s non-steroidal nature minimizes endocrine side effects and allows for more consistent renal protection. Recent phase III trials report sustained reductions in proteinuria and slower eGFR decline, with a safety profile characterized by a lower incidence of hyperkalemia relative to spironolactone. Post-marketing surveillance and real-world studies continue to support its efficacy and tolerability in diverse populations, including elderly patients and those with diabetic nephropathy.

Guideline Recommendations

International guidelines now recognize the role of MRAs in selected patients with CKD and resistant hypertension. The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 update includes esaxerenone as an option for patients with persistent albuminuria despite maximal RAAS blockade, particularly when spironolactone is contraindicated or poorly tolerated. Careful titration, monitoring of serum potassium, and regular assessment of renal function are emphasized to maximize benefit and minimize risk.

Conclusion

Long-term treatment with esaxerenone offers a promising approach for preserving renal function in patients with hypertension and CKD. Its selective mechanism of action, favorable safety profile, and demonstrated efficacy in reducing proteinuria and slowing eGFR decline position it as a valuable addition to the nephrology therapeutic armamentarium. Ongoing research will further elucidate its role in broader patient populations, optimize dosing strategies, and refine its integration into evidence-based care pathways.